Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 15

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 15
---
 the molecular level is essential to advancing patient careOur novel high-capacity adenovirus (HCAd) platform enables locally-administered genetic medicines to boost cellular production of therapeutic proteins and to mimic the body’s natural response to disease 
 New product development focusing on validated mechanisms of action in need of delivery, safety or durability enhancements                                                                                                                                                                  | ​ |

THE BENEFITS

| ​ |     | ​ | ​ | Precise, targeted treatments have transformative potential in treating painTargeted, disease-modifying treatments with safe and durable efficacy would be clinically and economically meaningful to patients and the healthcare system 
 Pacira is at the forefront of this shift with a long history of leadership in best-in-class, locally administered, and long-acting opioid-sparing pain management                                                                      | ​ |

Pacira BioSciences, Inc. 2025 Proxy Statement | 7

TABLE OF CONTENTS 2025 PROXY STATEMENT SUMMARY

Stockholder Engagement Throughout the year, we encourage our stockholders to communicate the matters most important to them. We also regularly provide stockholders and the general public with updates and other relevant information through our Investor Relations page on our corporate website under the “Investors” section of our website, which is located at www.pacira.com . Key themes of our stockholder engagement in 2024 included our business strategy, corporate governance and our board refreshment, our new management team and CEO, our capital allocation strategy (including advancing our pipeline, refinancing our debt, and the implementation of a stock repurchase program), as well as our intellectual property and exclusivity runway. We also hold quarterly conference calls during which management hosts a question-and-answer session following a set of prepared remarks, and frequently participate in industry and financial conferences. See “Communication with the Board” on page 35for more information on how to provide us with feedback.

| ​ | ​ | Since our annual meeting in 2024, we have contacted stockholders representing over 90% of our weighted average common stock outstanding | ​ | ​ |

| ​ | ​ | 5x30 Path to Growth and Value Creation​                                                     |     | ​ | ​ |
| ​ | ​ | The company intends to achieve the following five objectives by 2030 (“5x30”):              
 •                                                                                           
 Patients:   More than three million patients treated per year                               
 ​                                                                                           
 •                                                                                           
 Product revenue:   Double-digit compounded annual growth rate                               
 ​                                                                                           
 •                                                                                           
 Profitability:   Five percentage point gross margin improvement over 2024